Pharmacogenetics for off-patent antipsychotics: reframing the risk for tardive dyskinesia and access to essential medicines

Author： Ozdemir Vural   Aklillu Eleni   Mee Steven   Bertilsson Leif   Albers Lawrence J   Graham Janice E   Caligiuri Michael   Lohr James B   Reist Christopher  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.7, Iss.2, 2006-02, pp. : 119-133

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Less tardive dyskinesia of little value with later antipsychotics

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 542, 2007-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

The risk of tardive dyskinesia appears to be lower for olanzapine (2.5-20mg) than for conventional antipsychotics

By  

Inpharma, Vol. 1, Iss. 1483, 2005-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

'Biogenerics': the off-patent biotech products

By Schellekens H.   Ryff J.-C.  

Trends in Pharmacological Sciences, Vol. 23, Iss. 3, 2002-03 ,pp. : 119-121

Elsevier

Access to resources Recommend Favorite

Antipsychotics: Tardive tongue dyskinesia and burning mouth syndrome treated with botulinum toxin A: case report

By  

Reactions Weekly, Vol. 1, Iss. 1258, 2009-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Antidepressants/antipsychotics: Tardive dyskinesia (first report with tianeptine and reboxetine) in an elderly patient, treated with botulinum toxin A: case report

By  

Reactions Weekly, Vol. 1, Iss. 1348-1349, 2011-01 ,pp. : 6-7

Adis International

Access to resources Recommend Favorite